AMGN
Amgen Inc.
Drug Manufacturers - General · Healthcare · United States
460.73
close · 2026-10-29
value
62
cheaper than peers62
quality
66
stronger fundamentals66
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 4.6% | 76 |
| cash flow yield, 3 years ago | 3.9% | 76 |
| earnings yield, 2 years ago | 3.0% | 76 |
| earnings yield, latest year | 3.4% | 73 |
| earnings yield, 3 years ago | 2.9% | 71 |
| cash flow yield, 2 years ago | 3.3% | 67 |
| earnings yield, 1 year ago | 1.8% | 65 |
| cash flow yield, latest year | 3.6% | 56 |
| EV to EBITDA | 14.76× | 53 |
| forward P/E | 18.81× | 52 |
| price to sales | 5.91× | 39 |
| price to book | 21.31× | 7 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 101.3% | 98 |
| operating margin | 33.8% | 95 |
| revenue growth | 5.8% | 40 |
| debt to equity | 623.8% | 4 |
4 of 4 measures available
Facts
| market cap | $249B |
| free cash flow | $7.44B |
| employees | 31,500 |
| first trade | 1983-06-17 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | 14.23 | 7.56 | 12.49 | 12.11 | not reported |
| free cash flow | $8.10B | $10.39B | $7.36B | $8.79B | not reported |
| net income | $7.71B | $4.09B | $6.72B | $6.55B | not reported |
| revenue | $36.75B | $33.42B | $28.19B | $26.32B | not reported |
| unusual items | not reported | not reported | $0 | $0 | -$1.50B |